Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Hepatocellular carcinoma is one of the most intractable primary malignancies in the hepatobiliary and pancreatic tract with a poor overall survival worldwide. Unfortunately, the vast majority of hepatocellular carcinoma patients suffer from advanced unresectable or metastatic disease at diagnosis. Currently targeted therapy alone, or in combination with anti-vascular endothelial growth factor antagonist, is the standard first-line treatment for metastatic hepatocellular carcinoma. On the other hand, there is growing evidence suggesting that radiation therapy (external or internal) with or wit

Trial Details

NCT ID
NCT05809869
Phase
PHASE2
Sponsor
The University of Hong Kong
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Durvalumab
  • Tremelimumab
  • Yttrium-90 radioembolisation
Locations (sample)
  • Hong Kong, Hong Kong|22.27832,114.17469

Key Eligibility Criteria

  • Metastatic hepatocellular carcinoma (HCC) confirmed by radiological findings with contrast-enhanced triphasic CT scan of the liver and/or MRI scan …
  • Must be of age 18 years or above.
  • Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry.
  • Must be eligible to receive immune checkpoint inhibitor and yttrium-90 microsphere injection.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →